Targeting Tmprss2, S-protein:Ace2, and 3CLpro for Synergetic Inhibitory Engagement Mathew Coban1, Juliet Morrison PhD2, William D. Freeman MD3, Evette Radisky PhD1, Karine G. Le Roch PhD4, Thomas R. Caulfield, PhD1,5-8 Affiliations 1 Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL, 32224 USA 2 Department of Microbiology and Plant Pathology, University of California, Riverside, 900 University, Riverside, CA, 92521 USA 3 Department of Neurology, Mayo Clinic, 4500 San Pablo South, Jacksonville, FL, 32224 USA 4Department of Molecular, Cell and Systems Biology, University of California, Riverside, 900 University, Riverside, CA, 92521 USA 5 Department of Neuroscience, Mayo Clinic, 4500 San Pablo South, Jacksonville, FL, 32224 USA 6 Department of Neurosurgery, Mayo Clinic, 4500 San Pablo South, Jacksonville, FL, 32224 USA 7 Department of Health Science Research (BSI), Mayo Clinic, 4500 San Pablo South, Jacksonville, FL, 32224 USA 8Department of Clinical Genomics (Enterprise), Mayo Clinic, Rochester, MN 55905, USA Correspondence to: Thomas R. Caulfield, PhD, Dept of Neuroscience, Cancer Biology, Neurosurgery, Health Science Research, & Clinical Genomics Mayo Clinic, 4500 San Pablo Road South Jacksonville, FL 32224 Telephone: +1 904-953-6072, E-mail:
[email protected] SUMMARY Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a devastating respiratory and inflammatory illness caused by a new coronavirus that is rapidly spreading throughout the human population. Over the past 6 months, SARS-CoV-2, the virus responsible for COVID-19, has already infected over 11.6 million (25% located in United States) and killed more than 540K people around the world. As we face one of the most challenging times in our recent history, there is an urgent need to identify drug candidates that can attack SARS-CoV-2 on multiple fronts.